Dermal elastolysis in the setting of combination immunotherapy. (17th June 2019)

• Record Type: Journal Article
• Authors: Dickinson, Kirsten E.; Price, Lulit; Wanat, Karolyn A.; Swick, Brian L.
• Is Part Of: Journal of cutaneous pathology. Volume 46:Number 9(2019)
• Page Start: 684
• Page End: 687
• Publication Date: 2019-06-17
• Subjects: cabirlizumab -- elastolysis -- immunotherapy -- nivolumab; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.13492
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract : Multiple cutaneous side effects have been reported with the use of immunotherapies including programmed cell death protein 1 inhibitors. We report 2 patients who presented with papillary dermal elastolysis presenting as multiple, skin‐colored, wrinkled papules and atrophic macules following an inflammatory eruption in the setting of combination chemotherapy with nivolumab and cabiralizumab. These two cases highlight a novel finding, elastolysis in the setting of chemotherapy with nivolumab and cabiralizumab.